Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H18O2 |
Molecular Weight | 206.2808 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
InChI
InChIKey=HEFNNWSXXWATRW-UHFFFAOYSA-N
InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
Molecular Formula | C13H18O2 |
Molecular Weight | 206.2808 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f516c51-a1b5-4585-8de3-6271ad161608Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20718179
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f516c51-a1b5-4585-8de3-6271ad161608
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20718179
Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are thought to act through inhibition of prostaglandin synthesis. It’s used temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps and temporarily reduces fever. The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15481334 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | IBU-TAB Approved Usetemporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date5.8717438E11 |
|||
Palliative | IBU-TAB Approved Usetemporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date5.8717438E11 |
|||
Palliative | IBU-TAB Approved Usetemporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date5.8717438E11 |
|||
Palliative | IBU-TAB Approved Usetemporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date5.8717438E11 |
|||
Palliative | IBU-TAB Approved Usetemporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever Launch Date5.8717438E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.9 μg/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
IBUPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
103 μg × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
IBUPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.2 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
IBUPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
IBUPROFEN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
199800 mg single, oral Overdose Dose: 199800 mg Route: oral Route: single Dose: 199800 mg Sources: |
unknown, 17 years |
Other AEs: Cardiovascular collapse, Acidosis... Other AEs: Cardiovascular collapse (grade 5, 1 patient) Sources: Acidosis (grade 5, 1 patient) Hypothermia (grade 5, 1 patient) |
90 g single, oral Overdose |
unknown, 19 years |
Other AEs: Polyuria, Acidosis... |
800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: |
unhealthy, 33 years n = 40 Health Status: unhealthy Age Group: 33 years Sex: M+F Population Size: 40 Sources: |
Other AEs: Acute respiratory distress syndrome, Tachypnea... Other AEs: Acute respiratory distress syndrome (serious, 1 patient) Sources: Tachypnea (serious, 1 patient) Septic shock (serious, 1 patient) Breathlessness (serious, 1 patient) Septicemia (serious, 1 patient) |
400 mg 4 times / day multiple, intravenous Recommended Dose: 400 mg, 4 times / day Route: intravenous Route: multiple Dose: 400 mg, 4 times / day Sources: Page: p.87 |
unhealthy, 42 years (range: 17-73 years) n = 195 Health Status: unhealthy Age Group: 42 years (range: 17-73 years) Sex: M+F Population Size: 195 Sources: Page: p.87 |
Disc. AE: Dizziness, Headache... AEs leading to discontinuation/dose reduction: Dizziness (2%) Sources: Page: p.87Headache (1 patient) |
800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: Page: p.87 |
unhealthy, 44 years (range: 20-69 years) n = 304 Health Status: unhealthy Age Group: 44 years (range: 20-69 years) Sex: M+F Population Size: 304 Sources: Page: p.87 |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (2 patients) Sources: Page: p.87 |
240000 mg single, oral Overdose Dose: 240000 mg Route: oral Route: single Dose: 240000 mg Co-administed with:: divalproex sodium Sources: |
unknown, 49 years |
Other AEs: Cardiovascular collapse... Other AEs: Cardiovascular collapse (grade 5, 1 patient) Sources: |
240000 mg single, oral Overdose Dose: 240000 mg Route: oral Route: single Dose: 240000 mg Sources: |
unknown, 49 years |
Other AEs: Acidosis, Hypothermia... Other AEs: Acidosis (grade 5, 1 patient) Sources: Hypothermia (grade 5, 1 patient) |
400 mg 4 times / day multiple, intravenous Recommended Dose: 400 mg, 4 times / day Route: intravenous Route: multiple Dose: 400 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Pain Age Group: adult Sources: |
Other AEs: Myocardial infarction, Stroke... Other AEs: Myocardial infarction (serious|grade 5) Sources: Stroke (serious|grade 5) |
400 mg 6 times / day multiple, oral Recommended Dose: 400 mg, 6 times / day Route: oral Route: multiple Dose: 400 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
Other AEs: Myocardial infarction, Stroke... Other AEs: Myocardial infarction (serious|grade 5) Sources: Stroke (serious|grade 5) |
200 mg single, oral Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: |
unhealthy n = 62 Health Status: unhealthy Condition: Episodic Tension Type Headache Population Size: 62 Sources: |
Other AEs: Depression, Insomnia... Other AEs: Depression (below serious, 1 patient) Sources: Insomnia (below serious, 1 patient) Oropharyngeal pain (below serious, 1 patient) Sinus congestion (below serious, 1 patient) |
97.5 mg 4 times / day multiple, oral Dose: 97.5 mg, 4 times / day Route: oral Route: multiple Dose: 97.5 mg, 4 times / day Sources: |
unhealthy n = 112 Health Status: unhealthy Condition: Dental Pain Population Size: 112 Sources: |
Other AEs: Facial swelling... Other AEs: Facial swelling (below serious, 8 patients) Sources: |
10 mg/kg single, oral Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unhealthy n = 29 Health Status: unhealthy Condition: Post-ERCP Pancreatitis Population Size: 29 Sources: |
Other AEs: Bleeding, Perforation... Other AEs: Bleeding (below serious, 2 patients) Sources: Perforation (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Acidosis | grade 5, 1 patient | 199800 mg single, oral Overdose Dose: 199800 mg Route: oral Route: single Dose: 199800 mg Sources: |
unknown, 17 years |
Cardiovascular collapse | grade 5, 1 patient | 199800 mg single, oral Overdose Dose: 199800 mg Route: oral Route: single Dose: 199800 mg Sources: |
unknown, 17 years |
Hypothermia | grade 5, 1 patient | 199800 mg single, oral Overdose Dose: 199800 mg Route: oral Route: single Dose: 199800 mg Sources: |
unknown, 17 years |
Acidosis | 1 patient | 90 g single, oral Overdose |
unknown, 19 years |
Polyuria | 1 patient | 90 g single, oral Overdose |
unknown, 19 years |
Acute respiratory distress syndrome | serious, 1 patient | 800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: |
unhealthy, 33 years n = 40 Health Status: unhealthy Age Group: 33 years Sex: M+F Population Size: 40 Sources: |
Breathlessness | serious, 1 patient | 800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: |
unhealthy, 33 years n = 40 Health Status: unhealthy Age Group: 33 years Sex: M+F Population Size: 40 Sources: |
Septic shock | serious, 1 patient | 800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: |
unhealthy, 33 years n = 40 Health Status: unhealthy Age Group: 33 years Sex: M+F Population Size: 40 Sources: |
Septicemia | serious, 1 patient | 800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: |
unhealthy, 33 years n = 40 Health Status: unhealthy Age Group: 33 years Sex: M+F Population Size: 40 Sources: |
Tachypnea | serious, 1 patient | 800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: |
unhealthy, 33 years n = 40 Health Status: unhealthy Age Group: 33 years Sex: M+F Population Size: 40 Sources: |
Headache | 1 patient Disc. AE |
400 mg 4 times / day multiple, intravenous Recommended Dose: 400 mg, 4 times / day Route: intravenous Route: multiple Dose: 400 mg, 4 times / day Sources: Page: p.87 |
unhealthy, 42 years (range: 17-73 years) n = 195 Health Status: unhealthy Age Group: 42 years (range: 17-73 years) Sex: M+F Population Size: 195 Sources: Page: p.87 |
Dizziness | 2% Disc. AE |
400 mg 4 times / day multiple, intravenous Recommended Dose: 400 mg, 4 times / day Route: intravenous Route: multiple Dose: 400 mg, 4 times / day Sources: Page: p.87 |
unhealthy, 42 years (range: 17-73 years) n = 195 Health Status: unhealthy Age Group: 42 years (range: 17-73 years) Sex: M+F Population Size: 195 Sources: Page: p.87 |
Headache | 2 patients Disc. AE |
800 mg 4 times / day multiple, intravenous Recommended Dose: 800 mg, 4 times / day Route: intravenous Route: multiple Dose: 800 mg, 4 times / day Sources: Page: p.87 |
unhealthy, 44 years (range: 20-69 years) n = 304 Health Status: unhealthy Age Group: 44 years (range: 20-69 years) Sex: M+F Population Size: 304 Sources: Page: p.87 |
Cardiovascular collapse | grade 5, 1 patient | 240000 mg single, oral Overdose Dose: 240000 mg Route: oral Route: single Dose: 240000 mg Co-administed with:: divalproex sodium Sources: |
unknown, 49 years |
Acidosis | grade 5, 1 patient | 240000 mg single, oral Overdose Dose: 240000 mg Route: oral Route: single Dose: 240000 mg Sources: |
unknown, 49 years |
Hypothermia | grade 5, 1 patient | 240000 mg single, oral Overdose Dose: 240000 mg Route: oral Route: single Dose: 240000 mg Sources: |
unknown, 49 years |
Myocardial infarction | serious|grade 5 | 400 mg 4 times / day multiple, intravenous Recommended Dose: 400 mg, 4 times / day Route: intravenous Route: multiple Dose: 400 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Pain Age Group: adult Sources: |
Stroke | serious|grade 5 | 400 mg 4 times / day multiple, intravenous Recommended Dose: 400 mg, 4 times / day Route: intravenous Route: multiple Dose: 400 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Pain Age Group: adult Sources: |
Myocardial infarction | serious|grade 5 | 400 mg 6 times / day multiple, oral Recommended Dose: 400 mg, 6 times / day Route: oral Route: multiple Dose: 400 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
Stroke | serious|grade 5 | 400 mg 6 times / day multiple, oral Recommended Dose: 400 mg, 6 times / day Route: oral Route: multiple Dose: 400 mg, 6 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: pain Age Group: adult Sources: |
Depression | below serious, 1 patient | 200 mg single, oral Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: |
unhealthy n = 62 Health Status: unhealthy Condition: Episodic Tension Type Headache Population Size: 62 Sources: |
Insomnia | below serious, 1 patient | 200 mg single, oral Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: |
unhealthy n = 62 Health Status: unhealthy Condition: Episodic Tension Type Headache Population Size: 62 Sources: |
Oropharyngeal pain | below serious, 1 patient | 200 mg single, oral Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: |
unhealthy n = 62 Health Status: unhealthy Condition: Episodic Tension Type Headache Population Size: 62 Sources: |
Sinus congestion | below serious, 1 patient | 200 mg single, oral Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: |
unhealthy n = 62 Health Status: unhealthy Condition: Episodic Tension Type Headache Population Size: 62 Sources: |
Facial swelling | below serious, 8 patients | 97.5 mg 4 times / day multiple, oral Dose: 97.5 mg, 4 times / day Route: oral Route: multiple Dose: 97.5 mg, 4 times / day Sources: |
unhealthy n = 112 Health Status: unhealthy Condition: Dental Pain Population Size: 112 Sources: |
Perforation | below serious, 1 patient | 10 mg/kg single, oral Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unhealthy n = 29 Health Status: unhealthy Condition: Post-ERCP Pancreatitis Population Size: 29 Sources: |
Bleeding | below serious, 2 patients | 10 mg/kg single, oral Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unhealthy n = 29 Health Status: unhealthy Condition: Post-ERCP Pancreatitis Population Size: 29 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 26.0 |
no | |||
Page: abstract |
yes [IC50 4.4 uM] | |||
Page: 8.0 |
yes | |||
Page: abstract |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 867.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 37.0 |
minor | |||
Page: 2.0 |
minor | |||
Page: 2.0 |
minor | |||
Page: 37.0 |
no | |||
Page: 37.0 |
no | |||
Page: 37.0 |
no | |||
Page: 37.0 |
no | |||
Page: 2.0 |
no | |||
Page: 2.0 |
no | |||
Page: 701.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes | |||
Page: 2.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 5.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Letter: Aspirin sensitivity: other drugs. | 1975 Feb |
|
[Renal tubular acidosis with severe hypokalemic tetraparesis after ibuprofen intake]. | 1999 Apr 23 |
|
Recurrence of ibuprofen-induced aseptic meningitis in an otherwise healthy patient. | 1999 Feb |
|
Topical non-steroidal drugs are systemically absorbed and may cause renal disease. | 1999 Jan |
|
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts. | 1999 Jun |
|
Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. | 1999 May |
|
Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. | 1999 May 21 |
|
Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms. | 1999 Nov-Dec |
|
Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone inhibits expression of P2Y receptors in cystic fibrosis tracheal gland cells. | 1999 Oct |
|
Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival. | 1999 Sep |
|
Interstitial nephritis in children with Crohn's disease. | 2000 Apr |
|
Sensitivity of repeated interdigital web pinching to detect antinociceptive effects of ibuprofen. | 2000 Apr |
|
Thioesterification of 2-arylpropionic acids by recombinant acyl-coenzyme A synthetases (ACS1 and ACS2). | 2000 Apr |
|
Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. | 2000 Aug 11 |
|
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. | 2000 Feb 11 |
|
Regulation of endothelial nitric oxide synthase by PGD(2) in the developing choroid. | 2000 Jan |
|
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells. | 2000 Nov 17 |
|
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. | 2000 Sep 7 |
|
A benefit/risk analysis of the prevention of brain ischaemia with anticoagulant drugs: when, how and whom to treat? | 2001 |
|
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
Obsessive-compulsive disorder: a neuronal membrane phospholipid hypothesis and concomitant therapeutic strategy. | 2001 Apr |
|
Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. | 2001 Apr |
|
Induced accumulation of 2-hydroxy-4,7-dimethoxy-1,4-benzoxazin-3-one glucoside (HDMBOA-Glc) in maize leaves. | 2001 Apr |
|
The effect of standard care, ibuprofen, and music on pain relief and patient satisfaction in adults with musculoskeletal trauma. | 2001 Apr |
|
Esophageal laceration and charcoal mediastinum complicating gastric lavage. | 2001 Apr |
|
Determination of nonsteroidal anti-inflammatory drugs in biological fluids by automatic on-line integration of solid-phase extraction and capillary electrophoresis. | 2001 Feb |
|
Ibuprofen affects pro- and anti-inflammatory cytokine production by mononuclear cells of preterm newborns. | 2001 Feb |
|
The role of acetaminophen in the management of patients with osteoarthritis. | 2001 Feb 19 |
|
Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea. | 2001 Feb 20 |
|
Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry. | 2001 Feb 23 |
|
Ibuprofen versus indomethacin for closure of patent ductus arteriosus. | 2001 Feb 8 |
|
Activity profile of glycolamide ester prodrugs of ibuprofen. | 2001 Jan |
|
NSAID-induced nephrotoxicity from the fetus to the child. | 2001 Jan |
|
Is the combination of ibuprofen and caffeine effective for the treatment of a tension-type headache? | 2001 Jan |
|
Ibuprofen as a chemesthetic stimulus: evidence of a novel mechanism of throat irritation. | 2001 Jan |
|
Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs. | 2001 Jan 19 |
|
Allergic reactions due to ibuprofen in children. | 2001 Jan-Feb |
|
[Necrotizing fasciitis. Clinical criteria and risk factors]. | 2001 Mar |
|
Inhibitors of arachidonic acid metabolism have variable effects on calcium signaling pathways. | 2001 Mar |
|
Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough? | 2001 Mar |
|
Linear drug eruption. | 2001 Mar-Apr |
|
Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. | 2001 May |
|
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. | 2001 May |
|
Indomethacin and telomerase activity in tumor growth retardation. | 2001 May |
|
Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. | 2001 May-Jun |
Patents
Sample Use Guides
adults: take 1 tablet every 4 to 6 hours while symptoms persist. If pain or fever does not respond to 1 tablet, 2 tablets may be used; do not exceed 6 tablets in 24 hours. Children under 12 years: ask a doctor.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24481441
Ibuprofen, in a 400-μM concentration, decreased the expression of Hsp70 by 23% in comparison with untreated cells, whereas other NSAID had no effect. Ibuprofen also decreased the expression of Hsp70 in H358, a human lung adenocarcinoma cell line, in a dose-dependent manner (from 0-400 uM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 19:35:06 UTC 2022
by
admin
on
Fri Dec 16 19:35:06 UTC 2022
|
Record UNII |
WK2XYI10QM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02AJ19
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
LIVERTOX |
NBK547845
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
NDF-RT |
N0000000160
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-VATC |
QM02AA13
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ATC |
G02CC01
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
7.1
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
FDA ORPHAN DRUG |
100896
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.4
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ATC |
M01AE51
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
NDF-RT |
N0000175721
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
EU-Orphan Drug |
EU/3/01/020
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-VATC |
QM01AE51
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-VATC |
QM01AE01
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-VATC |
QG02CC01
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
NDF-RT |
N0000175722
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ATC |
R02AX02
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ATC |
M01AE01
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ATC |
N02AJ08
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ATC |
C01EB16
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
PEDEA (AUTHORIZED: DUCTUS ATERIOSUS, PATENT)
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
29
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
2.1
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-ATC |
M02AA13
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
||
|
WHO-VATC |
QC01EB16
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M6189
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | Merck Index | ||
|
WK2XYI10QM
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
CHEMBL521
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
C561
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
WK2XYI10QM
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
1335508
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
15687-27-1
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
D007052
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
132922
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
58560-75-1
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
SUPERSEDED | |||
|
DB01050
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
2118
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
1407
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
5640
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | RxNorm | ||
|
2713
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
5855
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
239-784-6
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
139466-08-3
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
SUPERSEDED | |||
|
DTXSID5020732
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
256857
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
3099
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
IBUPROFEN
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odour, characteristic. Solubility: Practically insoluble in water; soluble in 1.5 parts of ethanol (~750 g/l) TS, in 2 parts of ether R and in 1.5 parts of acetone R. Category: Analgesic; anti-inflammatory. Storage: Ibuprofen should be kept in a well-closed container. Definition: Ibuprofen contains not less than 98.5% and not more than 100.5% of C13H18O2, calculated with reference to the dried substance. | ||
|
3672
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
43415
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
Ibuprofen
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
IBUPROFEN
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY | |||
|
SUB08098MIG
Created by
admin on Fri Dec 16 19:35:06 UTC 2022 , Edited by admin on Fri Dec 16 19:35:06 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MINOR
|
||
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MAXIMUM TOLERATED DOSE | PHARMACOKINETIC |
|
INDICATION BIOLOGICAL PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
PEDIATRICS PHARMACOKINETIC |
|
||
Cmax | PHARMACOKINETIC |
|
ROUTE OF ADMINSTRATION PHARMACOKINETIC |
|
||
Tmax | PHARMACOKINETIC |
|
FOOD EFFECT PHARMACOKINETIC |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||